Categories AlphaGraphs, Earnings, Industrials

Earnings: Highlights of General Electric’s Q3 2023 financial results

Engineering conglomerate The General Electric Company (NYSE: GE) on Tuesday reported net profit for the third quarter of 2023, compared to a loss last year.

General Electric Q3 2023 earnings infographic

The Boston-based company posted adjusted earnings of $0.82 per share for the September quarter, compared to a loss of $0.17 per share a year earlier. On an unadjusted basis, net profit from continuing operations was $84 million or $0.08 per share, compared to a loss of $313 million or $0.29 per share in the third quarter of 2022. Total revenues increased 20% year-over-year to $17.3 billion during the three-month period.

“At GE Aerospace, we continue to experience rapid growth driven by robust demand and solid execution, largely in Commercial Engines and Services. At GE Vernova, our Grid and now Onshore Wind businesses were both profitable this quarter and we expect their performance to continue to improve,” said Lawrence Culp, chief executive officer of GE.

Prior Performance

  • General Electric Q4 2022 earnings infographic

Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top